Literature DB >> 22481601

Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.

Mohammed Lamorde1, Pauline Byakika-Kibwika, Marta Boffito, Lillian Nabukeera, Jonathan Mayito, Jasper Ogwal-Okeng, John Tjia, David Back, Saye Khoo, Mairin Ryan, Concepta Merry.   

Abstract

We investigated the effect of food on the steady-state pharmacokinetics of lopinavir and ritonavir in 12 Ugandan patients receiving lopinavir coformulated with ritonavir (LPV/r) tablets using a crossover design. Intensive pharmacokinetic sampling was performed 7 days apart after LPV/r dosing under moderate fat, high fat, and fasted meal conditions. Lopinavir and ritonavir concentrations were determined by liquid chromatography and tandem mass spectrometry. Compared with the fasted state, a high fat meal reduced lopinavir and ritonavir area under the curve by 14% and 29%, respectively. With a moderate fat meal, area under the curve for both drugs was similar to the fasted state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481601      PMCID: PMC3817537          DOI: 10.1097/QAI.0b013e3182567a35

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  4 in total

1.  The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

Authors:  Cheri Enders Klein; Yi-Lin Chiu; Walid Awni; Tong Zhu; Renee S Heuser; Thao Doan; Joerg Breitenbach; John B Morris; Scott C Brun; George J Hanna
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-01       Impact factor: 3.731

2.  Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

Authors:  Laura Else; Victoria Watson; John Tjia; Andrew Hughes; Marco Siccardi; Saye Khoo; David Back
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-04-09       Impact factor: 3.205

3.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Authors:  C Wyen; U Fuhr; D Frank; R E Aarnoutse; T Klaassen; A Lazar; A Seeringer; O Doroshyenko; J C Kirchheiner; F Abdulrazik; N Schmeisser; C Lehmann; W Hein; E Schömig; D M Burger; G Fätkenheuer; A Jetter
Journal:  Clin Pharmacol Ther       Date:  2008-01-09       Impact factor: 6.875

  4 in total
  3 in total

1.  The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Grant Dorsey; Theodore Ruel; David Gingrich; Henriette J Scherpbier; Edmund Capparelli; Vincent Jullien; Sera L Young; Jane Achan; Albert Plenty; Edwin Charlebois; Moses Kamya; Diane Havlir; Francesca Aweeka
Journal:  Pediatr Infect Dis J       Date:  2015-03       Impact factor: 2.129

2.  Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Julia Mwesigwa; Jane Achan; Tamara Clark; Albert Plenty; Edwin Charlebois; Moses Kamya; Sera L Young; Monica Gandhi; Diane Havlir; Deborah Cohan; Francesca Aweeka
Journal:  J Clin Pharmacol       Date:  2013-09-21       Impact factor: 3.126

3.  "That's True Love:" Lived Experiences of Puerto Rican Perinatally HIV-Infected Youth within Their Families' Context.

Authors:  Georgina Silva-Suárez; Elena Bastida; Silvia E Rabionet; Consuelo Beck-Sagué; Irma Febo; Carmen D Zorrilla
Journal:  Int J Environ Res Public Health       Date:  2015-12-22       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.